BioSpace News Archive

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of targeted immunotherapies announced the appointment of three new members to its Scientific and Medical Advisory Board.

STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced preliminary results for the fourth quarter and fiscal year ended December 29, 2023.

Alentis Therapeutics announced that Dr. William Pao will join its Board of Directors as an independent member effective immediately.

ICON plc, a world-leading healthcare intelligence and clinical research organisation, launched its “Optimising biotech funding” whitepaper.

Novocure reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2023.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, highlighted its recent progress and outlined 2024 strategic priorities across its pipeline of mRNA cell therapy product candidates.

CollPlant Biotechnologies announced that Mr. Yehiel Tal, the Company’s CEO, will participate in the Octane Aesthetic Tech Forum, being held on January 25-26, 2024 in Newport Beach, CA.

Xilio Therapeutics, Inc. (Nasdaq: XLO) today highlighted recent advances across its clinical pipeline and reported encouraging preliminary safety data from the first three dose levels in the ongoing Phase 1 trial evaluating XTX301, a tumor-activated IL-12, in patients with advanced solid tumors.

Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS) is pleased to announce that Vivos is seeing positive preliminary metrics following its November 28, 2023 announcement regarding FDA 510(k) clearance of its CARE oral medical devices to treat severe OSA.

Medison Pharma announced their exclusive multi-national agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, to commercialize Libtayo®, a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in select European markets and additional markets around the world.